Service Overview

As a world-renowned gene therapy service provider in the field of ophthalmology, Ace Therapeutics not only provides a variety of eye disease gene therapy products, but also provides efficacy testing of corresponding products for global customers. For gene therapy products, it is necessary to collect sufficient product characterization data for clinical development, including preclinical in vitro testing of transgene expression and in vivo validation of protein product function based on syngeneic or xenograft tumor models. Based on advanced technology and years of research, our customizable potency testing services can be designed to best suit your project requirements and greatly assist your research.

• In Vitro Evaluation Based on Cell

Gene therapy products used in clinical research rely on cell-based in vitro evaluation of the product to generate a therapeutic protein encoded by a transgene. Different from traditional drugs, drug efficacy testing of gene therapy drugs involves the measurement of multiple steps such as carrier infectivity, transgene transcription and translation, protein product modification and function. At Ace Therapeutics, our scientists expertly perform multiple in vitro assays to validate the efficacy of gene therapy products. Commonly used methods include western blot (WB), enzyme-linked immunosorbent assay (ELISA), and flow cytometry (FCM).

• In Vivo Evaluation Based on Live Animals

The development of gene therapy products requires rigorous in vivo studies and quality control to ensure efficacy. At Ace Therapeutics, we have built the most refined service platform for in vivo using state-of-the-art technology to assess infection, transcription and produced protein levels, correct localization of protein products and validation of therapeutic effects on appropriate models, respectively. Various eye disease models such as mice, pigs, and goats can be established to verify the efficacy of drugs in immune-competent or immune-compromised mouse models and even non-human primate models.

Ace Therapeutics is committed to providing high-quality efficacy testing services for global customers' ophthalmic gene therapy products. Our testing services cover the entire gene therapy development process and evaluation trials in vitro or in vivo. As a leading service provider in the field of ophthalmology and gene therapy, we have excellent expertise and rich experience in the field of ophthalmology gene therapy to support your research. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!

• AAV Vector Development Services for Ocular Nucleic Acid-Based Therapy
• Lentiviral Vector Development Services for Ocular Nucleic Acid-Based Therapy
• Non-Viral Vector Development Services for Ocular Nucleic Acid-Based Therapy
• Recombinant Adeno-Associated Virus Vector Development Services for Ocular Nucleic Acid-Based Therapy
• Delivery System Development Services for Ocular Nucleic Acid-Based Therapy
• CRISPR/Cas9 Gene Editing Services for Ocular Nucleic Acid-Based Therapy
• Safety and Toxicology Assessment Services for Ocular Nucleic Acid-Based Therapy

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit